Starpharma today released its interim report and financial results for the half-year ended 31 December 2019.

Biotech Dispatch reported that AstraZeneca has paid Starpharma a $4.5 million milestone payment following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466. The article mentioned the long standing partnership between the two companies which is focused on using Starpharma’s DEP® drug delivery platform to enhance AstraZeneca’s medicines.

To read the full article click here

The Motley Fool reported a rise in Starpharma’s share price off the back of the announcement that its VivaGel® BV product will be launched in Asia by Mundipharma. The article highlighted that the deal is an important commercial opportunity for Starpharma with the product set to be accessible to more than 1.5 billion women.

To read the full article, click here

Starpharma today announced that VivaGel^® BV has been launched in Asia under the brand name BETADINE^TM BV Gel. The product has initially been launched in South East Asia, with further roll-out in additional Asian countries, as regulatory approvals are granted.  

BETADINE^TM BV Gel will be available over-the-counter (OTC), without the need to see a doctor or obtain a prescription. Asia is the third region to launch VivaGel^® BV and represents a large commercial opportunity with access to more than 1.5 billion women.

The Board of Starpharma is pleased to announce the appointment of Mr David McIntyre as an independent non-executive director, effective 1 March 2020.

Starpharma today announced it has received US$3 million (A$4.5 million) from AstraZeneca following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466 (DEP^® Bcl2/xL conjugate) in December.

In this issue: 

>> VivaGel^® BV launched in the UK

>> AstraZeneca first DEP^® product enters the clinic; triggers US$3M milestone

>> DEP^® cabazitaxel trial moves into phase 2 on positive results

>> Fleurstat BVgel marketing campaign; New Zealand launch planned

>> Dual strategy to achieve approval of the NDA in the US

>> Okamoto joins forces with Japanese government for STI prevention campaign

>> VivaGel^® condom receives regulatory approval in Europe

>> DEP^® docetaxel & DEP^® cabazitaxel clinical trial case studies

>> DEP^® irinotecan phase 1/2 trial

>> New candidate - DEP^® gemcitabine

>> GMP DEP^® facility licence

>> DEP^® combinations add further value

>> Outlook, recent news & events

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2019.

Starpharma today announced that AstraZeneca (LSE/STO/NYSE: AZN) has commenced a phase 1 clinical trial of AZD0466 (DEP^® Bcl2/xL conjugate) and the first patient has been successfully dosed. The trial will recruit patients with a range of cancers and will be conducted at 4-5 US sites.

Starpharma today announced that it has received a $4.9M R&D tax incentive refund which relates to the costs of research and development during the 2019 Financial Year. The refund is in respect of eligible R&D activities across Starpharma’s portfolio, including DEP^® and VivaGel^®.